SGP
SpyGlass Pharma, Inc. (NASDAQ)
Healthcare — Biotechnology
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was incorporated in 2019 and is based in Aliso Viejo, California.
Price History
Fundamentals
| Market Cap | $657.97M |
| P/E Ratio (TTM) | - |
| Forward P/E | -7.30 |
| EPS (TTM) | $-1.34 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | 0.64 |
| Recommendation | None |
| Analyst Target | $45.00 |
| Analysts | 5 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 56.8 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $32.44 |
| 52-Week Low | $17.06 |
| 50-Day Avg | $21.24 |
| 200-Day Avg | $23.60 |
| Avg Volume | 95.7K |
| Volume | 2.3K |
Performance Analysis
NEUTRALSGP presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:31 UTC
Back to Screener Export Report